BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment